Remdesivir is an experimental antiviral drug developed by Gilead Sciences, Inc. as a course of treatment for Covid-19. Gilead entered into a non-exclusive licensing agreement with Jubilant Life Sciences for distribution to 127 countries. Following this, Jubilant Life Sciences through its subsidiary Jubilant Generics has entered an exclusive agreement with Saptagir Laboratories to manufacture Remdesivir.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2RmKNds
via IFTTT
0 comments:
Post a Comment